| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56541df79a26070c6c2c585b54af47c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_979b97d4ef3e797f68eb0607941b3d1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f9ad6348a026bf3e6d9b68634bd5eb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8c2e751a1a796af21bc8b38abd9384e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2011-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1976e43b986c72df2578f41efc682e97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b59dbb408b73d82b455607b0b9707129
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dede63e146c1ae8760b90d414d302502 |
| publicationDate |
2012-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012057343-A1 |
| titleOfInvention |
Nad(p)h oxidase inhibitor, therapeutic agent for oxidative stress-related diseases, therapeutic method for oxidative stress-related diseases, and screening method |
| abstract |
Disclosed is an NAD(P)H oxidase inhibitor which contains a substance that activates a glucagon-like peptide receptor or a pharmaceutically acceptable salt of the substance. The substance may be a glucagon-like peptide, a derivative of a glucagon-like peptide, a dipeptidyl peptidase-4 inhibitor, or a combination of a glucagon-like peptide or a derivative of a glucagon-like peptide and a dipeptidyl peptidase-4 inhibitor. The glucagon-like peptide receptor is expressed in a plurality of tissues, and the NAD(P)H oxidase inhibitor inhibits NAD(P)H oxidase in a plurality of tissues. Consequently, the NAD(P)H oxidase inhibitor is highly versatile. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014065370-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014064811-A1 |
| priorityDate |
2010-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |